Accession Number:



Sustained Corticosteroid Release From a Novel Therapeutic Contact Lens Drug Delivery System for the Treatment of Ocular Inflammation and Corneal Neovascularization

Descriptive Note:

Technical Report,15 Apr 2015,14 Apr 2018

Corporate Author:

Schepens Eye Research Institute Boston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Thousands of soldiers experience eye injuries in combat per year. When such injuries occur, corticosteroid eye drops are prescribed in order to prevent ocular inflammation. However, eye drops have low bioavailability, with only 1-7 of the drug reaching the eye, and are often administered incorrectly. In addition, the frequent administration of drops as often as once per hour can be cumbersome and result in poor adherence. We propose that wearing a corticosteroid-eluting contact lens worn continuously for one week would be a more convenient alternative while providing greater bioavailability. In in vivo studies, rabbits wearing the TCL had aqueous humor AH concentrations of API greater than or equal to AH concentrations from rabbits given corticosteroid eye drops. Ocular distribution of drug with TCL wear was comparable to or greater than hourly drops through seven days of TCL wear. Optical clarity studies demonstrate light transmission greater than 95. We demonstrated efficacy of the TCL in rabbit models of anterior uveitis and corneal neovascularization.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology
  • Anatomy and Physiology

Distribution Statement: